AnnouncementSep 2026
Sep 2026 · Announcement For Incorporation Of Foreign Subsidiary Of The Company 21 Sep - Anlon Healthcare incorporated 90%-owned Nigeria subsidiary on September 20, 2026 to expand West African operations.
Source: Bse
Anlon Healthcare Limited (AHCL)
Small CapPharma stocks · Small cap · NSE
Anlon Healthcare Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result30 Jul, 05:26 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
78BullishSMA20 +76.4% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 64
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
AHCLD candles · FIT view+69.9%Latest close ₹26.97 on 2026-10-19
Bar
-0.7%
RSI
51
MACD hist
-0.94
52W pos
62%
2026-10-19O ₹27.15H ₹27.78L ₹26.20C ₹26.97Vol 77.1L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
AHCLNifty PharmaNifty 500
- AHCL
- +79.8%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +85.4 pp
Chart stats
19 Oct 2026- From 52W high
- -27.6%
- 52W range position
- 62%
- ATR (14)
- 7.2%
- Volume vs 20D
- 0.20x
- Avg traded value
- ₹90.7 Cr
- 20D price channel
- ₹23.2 - ₹37.2
₹37.2
₹10.4 - ₹37.2
₹1.9
Latest completed session
20-session average
100.7% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · WATCHLIST41
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad2
Revenue +79.0% · PAT -50.3% YoY
Technical
Bullish78
Price trend and sector-relative-strength timing.
Valuation
Legacy model-11.0%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence64
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 2/100PAT -50% YoY · margin compression · Rev +79% YoY · +72% QoQ
Filed 30 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹87.6 Cr | +79.0% | +72.1% |
| EBITDA | ₹15.6 Cr | +149.8% | +2.0% |
| Operating margin | 17.8% | -94 bps | -1225 bps |
| PAT | ₹8.3 Cr | -50.3% | -25.2% |
| PAT margin | 9.5% | -120 bps | -1229 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 52.50
- P/B
- 7.21
- EV/EBITDA
- 34.06
- Market Cap
- 1659.00Cr
Profitability
- ROE
- 18.40%
- ROCE
- 20.80%
- ROA
- 7.75%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 43.33%
- EPS 5Y
- 38.10%
- Revenue 3Y
- 43.33%
- EPS 3Y
- 38.10%
Balance Sheet
- Debt/Equity
- 0.19
- Interest Coverage
- 12.00×
- Altman Z
- 7.77
- Book Value
- 4.33
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- -59.00 Cr
- EPS TTM
- 0.54
Shareholding
- Promoter Hold
- 52.68%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 77%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 172+43.3% vs prev
Net Profit
₹ CrLatest: 29.0+38.1% vs prev
Return on Equity
%Latest: 12.6-51.4% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 51. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~43.3% over last month) — short-term momentum positive.
- RSI(14) at 51 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 28% off 52W high · 160% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
96
RS percentile
Stage 2 UptrendEstablished S2
1M return
+17.8%
3M return
+79.8%
6M return
+86.8%
1Y return
+117.5%
RS 1D
0
RS 20D
+3
Sector rank
#1
Industry rank
#11
Stage evidence
- Price is 62.1% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +17.2%.
- Both 3-month and 6-month returns are positive.
50-DMA
price above
200-DMA
price above
S2 entered
18 Aug 2026
S2 age
43 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 215.99+1.48%
RS vs Nifty 500216
Valuation & peers
U-Score 41 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 41 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation0/30
Growth18/25
Quality11/20
Balance Sheet9/15
Cash Flow0/10
Piotroski
6/9 (+3)
Penalties
0
Raw sum
41
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
41/100 · legacy band WATCHLIST
Positive drivers
- Growth contributes 18/25 to the score.
- Balance sheet contributes 9/15 to the score.
- Quality contributes 11/20 to the score.
Main drags
- Fair-value margin of safety is negative at -11.0%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Cash flow is weaker at 0/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
52.5
PB
7.2
EV/EBITDA
34.1
ROE
18.4%
ROCE
20.8%
FCF Yield
—
Debt/Equity
0.2
MoS
-11.0%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
41
Previous: 41
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-11.0%
Previous: -11.0%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
41
41
41
41
41
41
41
41
41
41
41
41
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹7.25
-271.8% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹24.3
-11.0% MoS
PEG
1.38
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
JAGSNPHARM
Small
Jagsonpal Pharmaceuticals Limited
Pharmaceuticals
match 166
58
32.2
17.3%
+29%
FAIR VALUE
WINDLAS
Small
Windlas Biotech Limited
Pharmaceuticals
match 165
48
31.6
12.2%
+36%
FAIR VALUE
BETA
Small
Beta Drugs Limited
Pharmaceuticals
match 164
44
48.7
18.8%
+13%
WATCHLIST
KOPRAN
Small
Kopran Limited
Pharmaceuticals
match 164
22
51.9
4.9%
-1785%
OVERVALUED
BAJAJHCARE
Small
Bajaj Healthcare Limited
Pharmaceuticals
match 164
24
19.7
8.3%
-1505%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Anlon Healthcare Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
64Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 42nd percentile of the scored universe and 31st percentile within Pharma. Main check: cash conversion is weak at 28/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
19 docs text-extracted · 5 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
42nd percentile
overall median 67 · Pharma: 31st pctile, median 70 · Small: 47th pctile, median 66
Evidence depth
Financial-only
19 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
28
weak · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
90
strong · capital discipline
Results
38
weak · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸ROCE is 20.8%.
Trust risks
- ▸Operating cash flow is negative at ₹-59 Cr.
- ▸Only 0 years of positive FCF.
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
- ▸OPM spread across recent quarters is 28.9%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Anlon Healthcare Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement As Per Regulation 30 Of SEBI LODR. 21 Sep - Shareholders approved share swap to acquire 44.94% Apiqo Organics and 47.41% Bizotic Lifescience; issue price ₹17.85.
Source: Bse
Credit rating
Announcement under Regulation 30 (LODR)-Credit Rating 15 Sep - Brickwork assigned BWR BBB/Stable rating to Anlon Healthcare’s ₹23.60 crore bank facilities.
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 17 Aug - We have attached herewith copy of newspaper advertisement for Annual General meeting. Kindly take the same on your record. Thank you.
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement Of Incorporated Of Subsidiary Company Of Anlon Healthcare Limited 9 Jul - Anlon Healthcare incorporated ANLON MEDICARE PRIVATE LIMITED on July 9, 2026, investing ₹11 lakh for 55% stake.
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement For Incorporation Of Subsidiary Company 11 Jul - Anlon Healthcare incorporated 65% subsidiary Anlon Biologics Pvt Ltd on July 10, 2026 for biologics expansion.
Source: Bse
Investor presentationJun 2026
Jun 2026 · PPT
Source: Bse
Concall transcriptJun 2026
Jun 2026 · Transcript
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Press Release / Media Release 30 May - Audited Q4/FY26 results: consolidated income ₹172.22 Cr, PAT ₹29.09 Cr; Bizotic Lifescience acquired.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 28 May
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.